Adrienne Marks, NP
Nurse Practitioner · Orange
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Adrienne Marks’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$20,742
Medicare paid this office $20,742 for 13 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
13 Original Medicare patients in 2024. Average age 68 · 85 and older 0% · Health risk score 0.90. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: Depression 75%.
The office billed $78,555, Medicare allowed $26,685 and paid $20,742; for 56 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$70,112
Pharmacies billed $70,112 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 278) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
215 generic and 63 brand-name prescriptions · $70,112 in drug cost · 12 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Spravato | 54 | $65,675 | $1,216 |
| Desvenlafaxine Succinate Er | 20 | $785 | $39 |
| Bupropion Xl | 18 | $389 | $22 |
| Dextroamphetamine-Amphet Er | 23 | $385 | $17 |
| Venlafaxine Hcl Er | 17 | $166 | $10 |
See all 10 drugs
| Spravato | 54 | $65,675 | $1,216 |
| Desvenlafaxine Succinate Er | 20 | $785 | $39 |
| Bupropion Xl | 18 | $389 | $22 |
| Dextroamphetamine-Amphet Er | 23 | $385 | $17 |
| Venlafaxine Hcl Er | 17 | $166 | $10 |
| Lithium Carbonate Er | 11 | $102 | $9 |
| Lamotrigine | 11 | $79 | $7 |
| Mirtazapine | 11 | $58 | $5 |
| Trazodone | 16 | $51 | $3 |
| Gabapentin | 11 | $39 | $4 |
Year by year
| 2024 | 278 | 18 | 0% (0) | 23% | $70,112 |
| 2023 | 215 | 18 | 0% (0) | 25% | $49,130 |
| 2022 | 62 | 11 | 0% (0) | None | $2,664 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Spravato | 30 | $35,084 | $1,169 |
| Dextroamphetamine-Amphet Er | 17 | $315 | $19 |
| Escitalopram | 11 | $130 | $12 |
| Risperidone | 12 | $111 | $9 |
| Lamotrigine | 13 | $90 | $7 |
| Trazodone | 11 | $50 | $5 |
Money from drug and device companies
$194 in 2025
| 2025 | 3 | 4 | None | $194 |
| 2024 | 6 | 20 | None | $627 |
| 2023 | 6 | 12 | None | $306 |
| 2022 | 1 | 1 | None | $29 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Argenx US | Vyvgart | $122 | 1 payment
|
| Abbvie | Vraylar | $47 | 2 payments
|
| Vanda Pharmaceuticals | Fanapt | $25 | 1 payment
|
See all 4 published payments
| Abbvie | Meals · 2025-06-11 | Vraylar | $21 |
| Argenx US | Meals · 2025-05-14 | Vyvgart | $122 |
| Abbvie | Meals · 2025-04-22 | Vraylar | $26 |
| Vanda Pharmaceuticals | Meals · 2025-03-17 | Fanapt | $25 |
See earlier years (2024, 2023, 2022)
2024: $627
| Supernus Pharmaceuticals | Qelbree | $342 | 9 payments
|
| Janssen Pharmaceuticals | Spravato | $88 | 3 payments
|
| Almatica Pharma | Loreev Xr | $79 | 3 payments
|
| Abbvie | Vraylar | $57 | 3 payments
|
| Lundbeck | Rexulti | $34 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $28 | 1 payment
|
2023: $306
| Lundbeck | Rexulti | $85 | 3 payments
|
| Almatica Pharma | Loreev Xr | $77 | 3 payments
|
| Supernus Pharmaceuticals | Qelbree | $49 | 3 payments
|
| Iti | Caplyta | $33 | 1 payment
|
| Axsome Therapeutics | Auvelity | $32 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $32 | 1 payment
|
2022: $29
| Lundbeck | Rexulti | $29 | 1 payment
|
Professional record
- NPI
- 1467989814
- Licence
- CA 95010110, CA 95079340
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LP2300X (363LP2300X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-05-16
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.